Please login to the form below

Not currently logged in


This page shows the latest Arcoxia news and features for those working in and with pharma, biotech and healthcare.

Grunenthal to market MSD’s pain drug

Grunenthal to market MSD’s pain drug

In these countries, Grünenthal will hold exclusive promotion and distribution rights to the COX-2 inhibitor etoricoxib under the brand name Arcoxia. ... During this time Arcoxia has made a substantial amount of money for MSD - known as Merck &Co in the

Latest news

  • Icon Icon

    Hotfoot from seeing Madonna at the New York Superbowl, Stephanie Berman gives us some inspired thoughts on the power of branding - PMLiVE

  • New Accounts, April, 2009 - Advertising

    MSD  . Arcoxia . Arthritis . RFA Advertising . NAPP . New product . Oncology . RFA Advertising .

  • New Accounts, March, 2009 - Advertising

    MSD  . Arcoxia . Arthritis . RFA Advertising . NAPP  . Depocyte . Oncology. RFA Advertising .

  • New Accounts, February, 2009 - Advertising

    Merck Serono  . N/A . Corporate . Life Healthcare Communications  . MSD/ Schering-Plough  . Ezetrol . Cardiology . RFA Advertising . MSD. Singulair . Asthma . RFA Advertising . MSD  . Arcoxia . Arthritis . RFA Advertising . NAPP  .

  • Merck lambasted over semi-revelation

    Merck claimed that the product is the most widely prescribed traditional NSAID in the world', and hence was an appropriate comparator for Arcoxia. ... Also, people withdrawing due to oedema-related adverse effects was significantly higher than in

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...